Peri-operative anaesthetic myocardial preconditioning and protection – cellular mechanisms and clinical relevance in cardiac anaesthesia

G. Kunst¹ and A. A. Klein²

¹ Consultant, Department of Anaesthetics, King’s College Hospital NHS Foundation Trust, London, UK
² Consultant, Department of Anaesthesia and Intensive Care, Papworth Hospital, Cambridge, UK

Summary
Preconditioning has been shown to reduce myocardial damage caused by ischaemia–reperfusion injury peri-operatively. Volatile anaesthetic agents have the potential to provide myocardial protection by anaesthetic preconditioning and, in addition, they also mediate renal and cerebral protection. A number of proof-of-concept trials have confirmed that the experimental evidence can be translated into clinical practice with regard to postoperative markers of myocardial injury; however, this effect has not been ubiquitous. The clinical trials published to date have also been too small to investigate clinical outcome and mortality. Data from recent meta-analyses in cardiac anaesthesia are also not conclusive regarding intra-operative volatile anaesthesia. These inconclusive clinical results have led to great variability currently in the type of anaesthetic agent used during cardiac surgery. This review summarises experimentally proposed mechanisms of anaesthetic preconditioning, and assesses randomised controlled clinical trials in cardiac anaesthesia that have been aimed at translating experimental results into the clinical setting.

Introduction
In the UK, about 34 760 adult cardiac surgical procedures were carried out in 2011, including 17 070 coronary artery bypass graft (CABG) procedures, and 17 690 valvular repairs or replacements, many of which also required concurrent CABG. Overall mortality was 2.97% (see http://bluebook.scts.org). The population requiring surgery is older than before, with more patients presenting with multiple co-morbidities, including obesity, diabetes, chronic renal failure, and peripheral vascular disease [1], which increase the risk of postoperative complications [2, 3].

Extensive evidence from experimental studies has shown that volatile anaesthetics protect the heart from ischaemic myocardial injury in animal models, and that they also have the potential to provide renal and cerebral protection. Clinical proof-of-concept studies and meta-analyses based on small clinical studies have supported these experimental results, but inconclusively. However, whereas surgical myocardial protec-
tion and cardioplegic strategies are routinely employed to improve organ protection during cardiac surgery [4], management of general anaesthesia has remained basically unchanged over the last 20 years, with some anaesthetists using intravenous propofol only for maintenance, and others volatile anaesthetics alone, or volatile anaesthetics plus propofol in combination. This variation in clinical practice stems from a lack of evidence as to which type of anaesthetic is superior, and it demonstrates the potential for more protective anaesthesia if best practice could be conclusively demonstrated.

This article will provide a review of the current literature on mechanisms of anaesthetic protection by preconditioning in cardiac anaesthesia, and an overview of clinical trials assessing potentially protective anaesthetic regimens.

Methods
We performed a comprehensive literature review using MEDLINE and EMBASE, accessed via the National Health Service Healthcare Databases Advanced Search (HDAS) link. Articles from 2004 until 2014 were accessed with the following terms: volatile anaesthetics OR inhalation anaesthetics OR isoflurane OR sevoflurane AND myocardial protection OR preconditioning OR myocardial reperfusion injury OR cardiac protection OR myocardial ischaemia. Only studies written in the English language were considered. A total of 886 studies were identified, and based on their relevance to cellular mechanisms and clinical applications of myocardial conditioning by volatile anaesthetics in cardiac anaesthesia, we selected 97 for inclusion in this review.

Experimental evidence
Myocardial preconditioning describes the experimentally observed phenomenon that an intervention or a trigger, before a prolonged ischaemic insult to the myocardium, results in a reduction in the infarcted area. The preconditioning trigger can either be an ischaemic intervention or a pharmacological stimulus, such as volatile anaesthetics. Ischaemic preconditioning was first described in 1986 by Murry et al., who demonstrated in a dog model that four short episodes of 5 min of myocardial ischaemia, followed by 5 min of reperfusion, before a prolonged ischaemic period of 40 min, produced a ‘memory’ effect in the myocytes, that led to a 75% reduction in infarct size [5]. The pathophysiology of this phenomenon has subsequently been well described [6].

In addition to an immediate window of protection 1–2 h after the preconditioning stimulus, a delayed phase of protection from preconditioning, that persists for 2–3 days, has been described as late preconditioning [7]. Furthermore, the myocardium can also be protected by a stimulus that is applied after ischaemia–reperfusion injury [8]; this phenomenon is called post-conditioning, and has been reviewed elsewhere in this journal [9]. If the ischaemic stimulus for myocardial protection is applied at a distant organ or tissue such as a limb, the technique is called remote preconditioning, and is included in this thematic series [10].

The first experimental evidence of myocardial protection from ischaemia–reperfusion injury by volatile anaesthetics was obtained using halothane in a dog model, in the 1970s [11]. This protective effect was subsequently confirmed in the 1980s using halothane [12], enflurane [13] and isoflurane [14]. Volatile anaesthetic agents, however, have also been shown to induce the harmful phenomenon of ‘coronal steal’ in experimental models [15]. This describes the phenomenon where by vasodilation results in the shunting of blood flow away from the ischaemic myocardium, which then worsens myocardial ischaemia. Conflicting results in subsequent studies meant that by the early 1990s, the proposed phenomenon of coronary steal had been largely refuted [16]. More than 10 years after the first experimental description of preconditioning by an ischaemic trigger, preconditioning by an anaesthetic stimulus was described in 1997 by three independent groups, in rabbit models [17, 18] and in a dog model [19].

Two main intracellular signal transduction pathways, directing cardioprotection from cell surface receptors to convergent targets in the mitochondria, have been proposed as models to explain preconditioning: the reperfusion injury salvage kinases (RISK) pathway [20] via G-protein-coupled cell surface receptors; and the survivor-activating factor enhancement (SAFE) pathway [21]. The latter operates mainly through the tumour necrosis factor (TNF)-alpha receptor and signal transducer, and activator of transcription.
(STAT)-3. In the mitochondria, protection is triggered by inhibition of the opening of the mitochondrial permeability transition pore (mPTP) [22], and by activating the opening of the ATP-dependent potassium (KATP) channel [23]. Mitochondria supply ATP to cardiomyocytes, but they have also recently been identified as activators of cell death pathways; cell death can be inhibited by mitochondrial autophagy and pro-survival pathways, and mPTP plays an important role in modulating the balance of pro-survival over cell death pathways [24]. A recent study demonstrated that drug-induced activation of autophagy in rabbits before ischaemia, or during reperfusion, protected the myocardium from ischaemia–reperfusion injury [25].

The intracellular signal transduction proteins and molecules that are candidates for interactions with volatile anaesthetic agents are listed in Table 1 [26–57]. These interactions have been demonstrated in a number of experimental models in animals, in isolated perfused hearts (the so-called Langendorff heart apparatus), and also in human atrial myocardium and human embryonic stem cells. This body of evidence demonstrates that all three volatile anaesthetics currently in use (isoflurane, sevoflurane and desflurane), have the ability to protect myocardium not only in vivo in mammals, but also in vitro in human and animal myocardial tissue and cells.

In addition to protection in cardiac myocytes, direct endothelial protection by volatile anaesthetic agents has also been described, which may be of relevance for myocardial protection (Table 2 [58–64]).

It has been recently demonstrated that isoflurane (and also morphine) provides endothelial protection by preventing TNF-alpha-induced adhesion molecule expression in human umbilical vein endothelial cells [60], and more recently in volunteers anaesthetised with sevoflurane [61]. More detailed interactions and the individual signal transduction pathways of anaesthetic conditioning have been reviewed previously [8, 65–70].

Experimental investigations suggest that the ability of volatile anaesthetics to protect the myocardium by anaesthetic preconditioning significantly increases from isoflurane to sevoflurane to desflurane [71]. Not only the type of volatile anaesthetic, but also the duration and frequency of exposure to the volatile anaesthetic before ischaemia, have been shown to be of potential relevance in in-vitro experiments. In guinea pig hearts, exposure to sevoflurane for two periods of 5 min before a period of ischaemia, with a 5-min washout period in-between, showed improved protection compared with one single 15-min exposure to sevoflurane before ischaemia [72].

In addition to volatile anaesthetic agents, other drugs used in the peri-operative period may have an effect on anaesthetic preconditioning. In-vivo experiments in rabbits suggest that propofol may block preconditioning attributed to desflurane [73]. On the other hand, propofol may protect rat myocardium from ischaemia–reperfusion injury by up-regulation of nitric oxide synthase activity [74]. Interestingly, the combination of isoflurane preconditioning before cardiopulmonary bypass (CPB), and propofol during and after CPB, provided significantly improved myocardial protection in a dog model, compared with either agent alone [75]. Experimental data show that morphine enhances pharmacological preconditioning of isoflurane [76]. In addition, opioid infusions of remifentanil and sufentanil have been shown to protect human right atrial muscle from ischaemia–reperfusion injury in vitro [77]. Sulfonylureas are KATP channel blockers, and prevent myocardial preconditioning [78], and the beta-blocker metoprolol has been shown to block desflurane-induced preconditioning [79].

Experimental data have also suggested that co-morbidities such as diabetes/hyperglycaemia and obesity may attenuate the protective effects of volatile anaesthetics. Hyperglycaemia prevents isoflurane preconditioning in dogs in vivo, and also in human cardiomyocytes derived from induced pluripotent stem cells [80]. Sevoflurane-induced preconditioning was prevented by obesity [81] and reduced in isolated hypercholesterolaemic hearts from rats exposed to a high cholesterol diet, and in hypertrophied rat hearts, induced by transverse aortic constriction [82, 83]. Advanced age reduces myocardial protection provided by volatile anaesthetic agents, as demonstrated in guinea pig hearts [84] and also in human atrial cardiomyocytes [85].

The experimental evidence supports several hypotheses of molecular interactions by volatile anaesthetics resulting in potential myocardial protection;
Table 1 | Effects of volatile anaesthetic preconditioning on signal transduction proteins in cardiomyocytes.

| Myocyte | Protein | Experimental model | Volatile anaesthetic |
|---------|---------|--------------------|---------------------|
| Cytosol | PKC-delta activation preceded by ROS release | Rat myocardial trabeculae in vitro | Isoflurane [26] |
| PKC | PKC-delta and PKC-epsilon translocation, and Src PTK activation | Rat heart in vivo | Isoflurane [27] |
| PKC-epsilon and ERK1/2 | | Rat heart in vivo | Desflurane [28] |
| PKC-delta activation depends on modulation of Na+/Ca2+ exchanger | Right ventricular rat trabeculae in vitro | Sevoflurane [29] |
| PKC-epsilon activation | Rat cardiomyocytes | Isoflurane [30] |
| PKC-alpha and -epsilon translocation and activation | Guinea pig hearts in vitro | Sevoflurane [31] |
| PKC-delta, and -alpha activation, phosphorylation of Akt and GSK-3 beta, ERK1/2 activation | Human right atrial appendages, 3 cycles of preconditioning in vivo | Isoflurane and sevoflurane [32] |
| ERK1/2 | ERK1/2 triggered HIF-1alpha and VEGF up-regulation | Rat hearts in vivo | Isoflurane [33] |
| PI3K/Akt | PI3K/Akt activation and attenuation of myocardial apoptosis | Rabbit heart in vivo | Isoflurane [34] |
| S’AMP PK | S’AMP-activated protein kinase, ROS induced | Rat hearts in vitro | Sevoflurane [35] |
| Cyclooxygenase | Cyclooxygenase-2: critical mediator | Dog hearts in vivo | Isoflurane [36] |
| Caveolin-3 | Caveolin-3 expression and caveolae are critical mediators | Caveolin-3-knockout mice, hearts in vivo and cardiomyocytes in vitro | Isoflurane [37] |
| Caveolin-3-dependent cyclooxygenase-2 inhibition | Caveolin-3-knockout mice in vivo | Sevoflurane [38] |
| NO | NO release mediated protection | Rabbit hearts in vivo | Desflurane [39] |
| NOS | Activation of NOS | Rabbit hearts in vivo | Desflurane [40] |
| ROS | ROS generation from electron transport chain complex III | Rabbit hearts in vivo | Isoflurane [41] |
| ROS mediates attenuation of mitochondrial respiration complex I | Guinea pig myocardial mitochondria | Sevoflurane [42] |
| ROS generated PKC-alpha activation | Rat right ventricular trabeculae in vitro | Sevoflurane [43] |
| ROS generation | Human atrial trabeculae | Sevoflurane and desflurane [44] |
| ROS generation, and ROS dependent protection | Adult ventricular rat cardiomyocytes | Sevoflurane and desflurane [45] |
| ROS generation attenuation of complex I activity and ROS generation | Cardiomyocytes from hESC | Isoflurane [46] |
| Mitochondrium | Improved resistance of mPTP to Ca2+ induced opening | Rabbit hearts in vivo | Desflurane [48] |
| mPTP | mKATP activation induced mPTP inhibition | Rabbit hearts in vivo | Isoflurane [49] |
| Delayed opening of mPTP | Cardiomyocytes from hESC | Isoflurane [46] |
| Delayed opening of mPTP | Rat cardiomyocytes | Isoflurane [30] |
| O-GlcNAc modification of mitochondrial voltage-dependent anion channel inhibits opening of mPTP | Mouse myocytes | Isoflurane [50] |
| mKATP | Activation of mKATP channels | Rabbit hearts in vivo | Isoflurane [49] |
| Activation of human cardiac mKATP channels | Lipid bilayers | Isoflurane [51] |
| BKca | Activation of BKca (PKA mediated) | Mouse hearts in vivo | Desflurane [52] |
however, the limitations of the experimental set-ups do need to be considered. For example, in-vivo animal models may experience variable collateral blood flow, which can potentially interfere with the infarct size, and is difficult to control for. This issue is avoided in tissue models such as human atrial trabeculae, and also in single cardiomyocytes. However, human atrial muscle has different subtypes of contractile and metabolic proteins compared with ventricular myocytes, which may alter the response to ischaemia of atrial muscle cells compared with those of ventricular myocytes. Isolated adult cardiomyocytes lose important pathophysiological aspects of myocardial ischaemia–reperfusion injury. In the whole heart, hyper-contraction of myocytes, causing sarcolemmal and cytoskeletal disruption, results in massive enzyme release, influx of calcium ions into broken cells, and interstitial oedema during reperfusion, after an ischaemic insult. Both hyper-contraction and interstitial oedema do not occur during reperfusion in isolated adult cardiomyocytes [86].

On the other hand, embryonic cells (including human embryonic stem cell-derived cardiomyocytes), which have the advantage of a non-animal model, and

Table 1  (continued)

| Myocyte | Protein | Experimental model | Volatile anaesthetic |
|---------|---------|--------------------|---------------------|
| Cell nucleus | NF-kappa B | Attenuation of NF-kappa B activation at the end of I-R | Rat hearts in vitro | Sevoflurane [53] |
| | | Activation of NF-kappa B, up-regulation of autophagy, decreased apoptosis before I/R | Rat hearts in vitro | Sevoflurane [54] |
| | | Inhibition of NF-kappa B during I/R | Rat hearts in vivo | Sevoflurane [55] |
| | | Up-regulation of NF-kappa B and anti-apoptosis factors before I-R | Rat hearts in vivo | Sevoflurane [56] |
| HIF-1 alpha | | Activation of HIF-1 alpha | Rabbit hearts in vivo | Isoflurane [57] |

PKC, protein kinase C; ROS, reactive oxygen species; Src PTK, sarcoma protein tyrosine kinase; ERK, extracellular signal regulated kinase; Akt, protein kinase B; GSK, glycogen synthase kinase; HIF, hypoxia inducible factor; VEGF, vascular endothelial growth factor; PI3K, phosphoinositide 3-kinase; AMP, adenosine monophosphate; NO, nitric oxide; NOS, nitric oxide synthase; mPTP, mitochondrial permeability transition pore; mKATP channel, mitochondrial ATP-sensitive potassium channel; hESC, human embryonic stem cells; O-GlcNAc, O-linked beta-N-acetylglucosamine; BK Ca, large-conductance calcium-activated K+ channel; PKA, protein kinase A; NF, nuclear factor; I-R, cardiac ischaemia–reperfusion.

Table 2  Effects of volatile anaesthetic preconditioning on signal transduction proteins in endothelium.

| Endothelium | Inhibition of endothelial NF-kappa B activation | Human umbilical vein, endothelial cells | Desflurane [58] |
|-------------|-----------------------------------------------|----------------------------------------|----------------|
| | Inhibition of TNF-alpha-stimulated expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin | Human umbilical vein, endothelial cells | Desflurane [59] |
| | Prevention of TNF-alpha-induced adhesion molecule expression | Human umbilical vein, endothelial cells | Isoflurane [60] |
| | Inhibition of endothelial leucocyte adhesion | Human volunteers | Sevoflurane [61] |
| | Preservation of glycocalix from I-R-induced degradation by attenuation of lysosomal cathepsin B release | Guinea pig hearts in vitro | Sevoflurane [62] |
| | Endothelial protection against ischaemia mediated by PKCs and mKATP channels | Bovine pulmonary arterial endothelial cells | Desflurane [63] |
| | Nos (endothelial Nos and inducible Nos) | Nos knockout mice | Isoflurane [64] |

NF, nuclear factor; TNF, tumour necrosis factor; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular adhesion molecule-1; I-R, cardiac ischaemia–reperfusion; PKC, protein kinase C; mKATP channel, mitochondrial ATP-sensitive potassium channel; NOSs, nitric oxide synthases.
elimination of collateral blood flow and maintenance of contractility, have a completely different energy metabolism compared with adult cardiomyocytes. One feature is that the fetal heart relies on carbohydrate substrates such as lactate and glucose, thus tolerating a low oxygen environment much better than adult cardiomyocytes [87]. Membrane preparations with membrane proteins and applied patch-clamp techniques can measure and quantify interactions and modulation from volatile anaesthetic agents; however, these interactions cannot be shown to have a causal relationship with myocardial protection from ischaemia–reperfusion injury.

**Clinical evidence of anaesthetic preconditioning**

The very low incidence of hard clinical endpoints such as mortality and myocardial infarction in the postoperative period means that surrogate endpoints, such as postoperative troponin concentrations, are commonly used in proof-of-concept trials. While serum markers may reflect clinical outcome, their clinical importance as an appropriate endpoint remains open to debate [88].

Raised levels of troponin postoperatively have been shown to correlate strongly with worse clinical outcome [89]. In addition, postoperative troponin I correlates well with the mass of myocyte necrosis diagnosed by serial cardiac magnetic resonance imaging (MRI) after CABG surgery [90].

We have identified a number of small-to-medium-sized, prospective, randomised controlled proof-of-concept trials in which volatile anaesthetics induced a significant reduction in postoperative troponin levels in cardiac surgery [91–103], summarised in Table 3, and other, similarly-sized trials that did not demonstrate reduced postoperative troponin levels with volatile anaesthetics (Table 4 [104–117]).

In coronary surgery, Lee et al. demonstrated that isoflurane, if given at the beginning of CPB at 2.5 minimum alveolar concentration (MAC) before aortic cross-clamping, and with a 5-min washout period after its administration, significantly reduced the postoperative ischaemic marker troponin I at 24 h [92]. However, dose-related effects and application patterns, including several cycles of volatile anaesthetic preconditioning with washout intervals, were not investigated.

Amr and Yassin used the same anaesthetic preconditioning protocol with the application of 2% isoflurane followed by a 5-min washout period, to show that anaesthetic preconditioning reduced postoperative cardiac troponin I as much as the protection conferred by ischaemic preconditioning, and significantly more than in the control group, that received midazolam and no volatile anaesthetic agent [100]. In another small proof-of-concept trial by Meco et al., desflurane, given before CPB, resulted in myocardial protection and reduced cardiac troponin I postoperatively [96]. In contrast to the three trials mentioned above, where volatile anaesthetic agents were administered before placement of the aortic cross-clamp, De Hert et al. described significant reductions in postoperative cardiac troponin I after continuous administration of sevoflurane during surgery [91]. In the same study, sevoflurane was also administered only pre- or post-CPB, and this did not result in significant postoperative troponin changes compared with patients receiving propofol only. These results are confounding when compared with those described by Lee et al., Amr and Yassin and Meco et al., where the volatile anaesthetic was only given before CPB. However, all patients in De Hert et al.’s trial underwent CABG surgery with CPB and intermittent aortic cross-clamping, which potentially provided an additional ischaemic preconditioning stimulus, as well as adding additional reperfusion episodes. The improved myocardial protection may therefore have been a result of the combination of anaesthetic preconditioning during CPB, and ischaemic preconditioning caused by intermittent aortic cross-clamping [91].

Tritapepe et al., in a relatively large trial with 150 patients, demonstrated that the continuous administration of 1 MAC desflurane during CABG surgery, except during CPB, induced significant cardioprotection, as assessed by reduced postoperative cardiac troponin I levels, compared with propofol infusion [97]. In contrast to the study by de Hert et al., anterograde or retrograde cold blood cardioplegia was used to immobilise the myocardium during grafting, thus excluding an additional protective effect by cross-clamp defibrillation. Kawamura et al. showed a similar effect on postoperative myocardial ischaemic markers in a small cohort of 23 patients after continuous
| Procedure | Anaesthetic intervention | Control group | Analgesia | n  | Cardiac marker | Findings and effect sizes (reduction in cardiac marker)                                                                 | Reference |
|-----------|-------------------------|---------------|-----------|----|----------------|--------------------------------------------------------------------------------------------------------------------------|-----------|
| CABG      | Sevoflurane 0.5–2% pre/post-CPB or continuously | TCI propofol  | Remifentanil infusion | 200 | CTnI | Significantly lower increase in cTnI in the sevoflurane continuous group compared with the propofol group | [91]      |
| CABG      | Isoflurane 2.5 MAC at onset of CPB for 15 min before CC, 5-min washout | Propofol      | Fentanyl   | 40  | CTnI | Significant reduction in cTnI at 24 h after the surgery in the isoflurane group                                            | [92]      |
| AVR       | Sevoflurane 0.5–1%      | TCI propofol  | Remifentanil infusion | 30  | CTnI | Significant reduction in cTnI up to 24 h postoperatively in the sevoflurane group                                           | [93]      |
| OPCAB     | Desflurane 0.5–2 MAC during surgery | TCI propofol  | Fentanyl   | 112 | CTnI | Significant reduction of the cTnI AUC up to 24 h postoperatively                                                        | [94]      |
| CABG      | Sevoflurane 0.5–1.0% during surgery | Propofol      | Fentanyl   | 23  | CTnT | Significant reduction in peak cTnT up to 3 h after aortic declamping in the sevoflurane group                           | [95]      |
| CABG      | Desflurane 2.5% for 5 min during CPB before CC, 10-min washout | Propofol      | Fentanyl   | 28  | CTnI | Significant reduction in peak cTnI at 24 h and 72 h after surgery in the desflurane group                               | [96]      |
| CABG      | Desflurane 1 MAC during surgery, except during CPB time | TCI propofol  | Fentanyl   | 150 | CTnI | 47% reduction of the cTnI AUC in the desflurane group                                                                  | [97]      |
| CABG      | Sevoflurane 1 MAC continuous vs intermittent (10-min washout) before CPB | Propofol      | Sufentanil | 42  | CTnT | Significant reduction in peak cTnT at 24 and 48 h postoperatively in the intermittent sevoflurane group                | [98]      |
| CABG      | Sevoflurane 1 MAC × 5 min vs 2 MAC × 5 min with 10-min washout before CPB | TCI propofol  | Sufentanil | 30  | CTnI | Significant reduction in peak cTnT up to 72 h postoperatively in the 1 × 5 min sevoflurane group                       | [99]      |
| CABG      | Isoflurane 2.5% 10 min before CC | Midazolam     | Sufentanil | 45  | CTnI | Significant reduction in peak cTnI up to 36 h postoperatively in the isoflurane group                                  | [100]     |
| OPCAB     | 1–2.5% Isoflurane during surgery | Propofol      | N₂O        | 45  | CTnT | Significant reduction in peak cTnT at 6 and 24 h after surgery in the isoflurane group                                 | [101]     |
| CABG      | Isoflurane 1–1.5 MAC until CPB and propofol during and after CPB; or isoflurane only | Propofol or midazolam | Fentanyl | 120 | CTnI | Isoflurane plus propofol reduced the cTnI AUC by 33% compared with iso only, and 35% compared with propofol only       | [102]     |
| OPCAB     | Sevoflurane 0.75/1.0/1.5 MAC | Midazolam     | Fentanyl   | 48  | CTnI | Significant reduction of cTnI peak levels at 24, 48 and 72 h after surgery in the 1.0 and 1.5 MAC groups                | [103]     |

CABG, coronary artery bypass graft surgery; CPB, cardiopulmonary bypass; TCI, target controlled infusion; CTnI, cardiac troponin I; MAC, minimal alveolar concentration; CC, aortic cross-clamp; AVR, aortic valve replacement surgery; OPCAB, off-pump coronary artery bypass graft surgery; AUC, area under the curve; CTnT, cardiac troponin T.
administration of sevolurane during CABG surgery, where patients received anterograde cold blood cardioplegia [95].

The washout period of the preconditioning trigger before the episode of critical ischaemia is part of the classical preconditioning protocol [5]. This technique was assessed by Frassdorf et al. and Bein et al. in patients undergoing CABG surgery with CPB [98, 99]. Their studies showed that only intermittent administration of sevolurane induced statistically relevant reductions in postoperative ischaemic markers, compared with one single episode of volatile anaesthetic administration before CPB. Bein et al. compared intermittent sevolurane before CPB, with continuous administration of sevolurane before CPB, and Frassdorf et al. compared intermittent sevolurane with a single 5-min period of sevolurane before CPB. Both trials also included a control group receiving propofol only. However, the intermittent sevolurane regimen was not compared with sevolurane-only during the whole procedure, particularly during CPB. Clinical limitations of intermittent sevolurane applications, with washout periods in-between, include natural limits on the number of these washout periods before CPB, as the beginning of CPB should not be delayed. In addition, during the interruption of sevolurane, the administration of a different non-volatile anaesthetic regimen needs to be considered.

One recent small proof-of-concept trial by Huang et al. investigated the concept of whether sevolurane plus propofol anaesthesia would result in less myocardial damage during CABG surgery, compared with sevolurane, propofol or midazolam alone [102]. Sevolurane was administered before CPB, and propofol 100 μg.kg⁻¹.min⁻¹ was given during CPB, and until 15 min after aortic declamping, followed by propofol 60 μg.kg⁻¹.min⁻¹ after CPB. The results indicated that a combination of sevolurane preconditioning before CPB, and propofol protection during and after CPB, resulted in a significant reduction in postoperative markers of myocardial ischaemia, in contrast to the effects of either sevolurane or propofol anaesthesia alone. Propofol may protect the myocardium from ischaemia–reperfusion injury by scavenging peroxynitrite [118]. This effect can potentially be synergistic with the preconditioning effect of sevolurane, which generates small amounts of peroxynitrate before bypass that at low levels provides myocardial protection.

During CABG surgery without the use of CPB, sevolurane, desflurane or sevolurane administered during the whole procedure have been shown to reduce postoperative troponin concentrations [94, 101, 103], while during aortic valve replacement surgery, sevolurane has also been shown to reduce postoperative troponin levels [93]. Wang et al. investigated different doses of isoflurane during CABG surgery without CPB, and demonstrated that 1 MAC of sevolurane induced a significant reduction in postoperative troponin levels, whereas a lower dose of 0.75 MAC provided no protection, and a higher dose conferred no additional myocardial protection [103].

In contrast to the evidence presented up to now, there are a number of trials showing that volatile anaesthetic agents in cardiac surgery do not reduce postoperative troponin levels. Xia et al. demonstrated a protective effect of propofol in the clinical setting, when compared with isoflurane alone. High doses of propofol (120 μg.kg⁻¹.min⁻¹), from 10 min before CPB until 15 min after aortic unclamping, resulted in a significant reduction in postoperative troponin I, suggesting that a continuous infusion of high-dose propofol is more protective than either isoflurane or a lower-dose infusion of propofol [106]. One explanation for this confounding finding may be the long aortic cross-clamp time in all groups, which exceeded 80 min. Experimental data have shown previously that the therapeutic timeframe for anaesthetic preconditioning lies between 25 and 40 min [119]. Therefore, protection by the volatile anaesthetic agent may not have been observed in the study conducted by Xia et al. owing to the prolonged CPB and ischaemic time.

Flier et al. investigated a protocol with isoflurane given during the whole procedure [112]. Their results did not reveal any differences in postoperative troponin levels after maintenance of anaesthesia with propofol, in comparison with isoflurane. However, patients taking the K_\text{ATP} channel blocker sulphonylurea were not excluded from the study, and sulphonylureas are known to block the potentially cardioprotective effect of volatile anaesthetic agents. In addition, the intervention had to be discontinued in 13% of patients, and three patients were from the isoflurane group, which led to a potential
Table 4 Clinical trials comparing volatile anaesthesia with propofol anaesthesia in cardiac surgery that indicated the same amount of myocardial injury with volatile anaesthetics and propofol, with similar peri-operative troponin serum concentrations, or less myocardial injury and lower postoperative cardiac serum markers with propofol.

| Procedure | Anaesthetic intervention | Control group | Analgesia | n  | Cardiac marker | Other findings apart from no difference between postoperative biomarkers | Reference |
|-----------|--------------------------|---------------|-----------|----|----------------|---------------------------------------------------------------------|-----------|
| CABG      | Isoflurane 1 MAC for 5 min before CPB plus 5-min washout | Propofol      | Sufentanil | 34 | CTnI           | No difference between groups in postoperative CTnI peak values       | [104]     |
| MDCAB     | Sevoflurane 1 MAC during surgery | Propofol      | Remifentanil | 50 | CTnT           | No difference in postoperative cTnT values. After LAD occlusion. Preserved myocardial function with sevoflurane | [105]     |
| CABG      | Isoflurane 1–1.5% after induction during surgery | Propofol      | Fentanyl   | 54 | CTnT and cTnI | Significantly lower cTnI and cTnT levels at 8, 24 and 48 h after surgery in the high-dose propofol group compared with the other groups | [106]     |
| CABG      | Sevoflurane during surgery | Propofol      | Remifentanil | 18 | CTnI           | Similar AUC of postoperative cTnI in sevoflurane and propofol groups (up to 36 h) | [107]     |
| OPCAB     | Sevoflurane during surgery | Propofol      | Remifentanil | 20 | CTnT           | Similar postoperative cTnT release in sevoflurane and propofol groups. Different transcriptional response in sevoflurane group | [108]     |
| OPCAB     | Sevoflurane during surgery | Propofol      | Remifentanil | 120| CTnI          | Similar postoperative cTnT release in both groups. Significant difference in subgroup of patients with CAD (n = 20) with reduced cTnI peak levels postoperatively | [109]     |
| CABG      | Sevoflurane 1 MAC 15 min before CPB | Propofol      | Sufentanil | 72 | CTnI           | Similar AUC for postoperative cTnI concentrations (up to 12 h)       | [110]     |
| MVR       | Desflurane 0.5–2 MAC pre-CPB | Propofol      | Fentanyl   | 120| CTnI          | Similar postoperative cTnI release in both groups. Significant difference in subgroup of patients with CAD (n = 20) with reduced cTnI peak levels postoperatively | [111]     |
| CABG      | Desflurane/ sevoflurane > 0.5 MAC at least 30 min before CC until at least 10 min after CC | Propofol      | Not defined | 414| CTnI           | No difference in postoperative cTnI peak levels and AUC between groups | [112]     |
| CABG      | Isoflurane 0.5–1 MAC during surgery | Propofol      | Sufentanil | 84 | CTnI           | Similar postoperative cTnI peak levels in both groups                | [113]     |
| OPCAB     | Sevoflurane during surgery | Propofol      | Remifentanil | 94 | CTnI           | Similar postoperative cTnI levels in both groups                     | [114]     |
| OPCAB     | Sevoflurane 1.5–2.5% | Propofol      | Fentanyl   | 38 | CTnI           | Similar postoperative cTnI peak levels in both groups. Increased oxidative stress markers in propofol group | [115]     |
problem with statistical power [112]. Soro et al. compared three groups of patients, with one group receiving propofol only, the second group sevoflurane during surgery and the third receiving sevoflurane during surgery and postoperatively in the cardiac intensive care unit before tracheal extubation [116]. This study was designed as a double-blind trial, with sevoflurane administered using an infusion pump. There was no difference between the groups with regard to postoperative myocardial ischaemic markers. However, nearly half of the patients were diabetic, which might have blocked potential cardioprotective effects, and relatively low doses of sevoflurane (1 MAC) were used postoperatively, which may not have been high enough to induce significant myocardial protection [116]. Wang et al. reported that the administration of 1 MAC of isoflurane for 5 min, plus a 5-min washout before CPB, did not result in reduced postoperative troponin levels [104]. However, only a single application/washout period was included, which may have reduced the effect of the intervention. Similarly, Piriou et al. showed that 1 MAC of sevoflurane for 15 min before CPB had no effect compared with propofol [109]. Potential causes of the negative outcome of this trial include: the dose, which may have been too low; the administration pattern, which was not intermittent; and the administration time, which may have been too short and/or the wash-out period too long [109].

De Hert et al. assessed a large cohort of patients (n = 414) in a multicentre randomised trial; interestingly, they did not observe a change in postoperative troponin I peak levels in patients receiving volatile anaesthetics, compared with propofol anaesthesia. However, the protocol in this trial allowed the centres to administer sevoflurane or desflurane in different patterns. All patients received the volatile anaesthetic during CPB, and some patients in addition both before and/or after CPB. The type of analgesia was not fixed [111]. In contrast to the troponin I results, however, they observed trends in clinical outcomes in favour of volatile anaesthetics; the 1-year mortality was 12.3% in the propofol group, but only 3.3% in the sevoflurane and 6.7% in the desflurane groups, and the hospital length of stay was reduced in the group receiving volatile anaesthetics.

In contrast to Wang et al., who demonstrated a cardioprotective effect of sevoflurane during CABG without CPB [103], five other study groups did not observe a similar effect [107, 108, 113, 114, 117]. Three of these trials recruited small numbers of patients with n = 18, [107], n = 20 [108] and n = 38 [114], which may have contributed to the negative results, as they are likely to have been statistically underpowered. In addition, the relatively short duration of ischaemia during CABG without CPB, and the low doses of sevoflurane used, may have contributed to the confounding results. Ballester et al. assessed levels of oxidative stress

Table 4 (continued)

| Procedure     | Anaesthetic intervention | Control group | Analgesia | n  | Cardiac marker | Other findings apart from no difference between postoperative biomarkers | Reference |
|---------------|--------------------------|---------------|-----------|----|----------------|------------------------------------------------------------------------|-----------|
| MVR           | Sevoflurane 0.5–2 MAC pre- + post-CPB | Propofol | Fentanyl | 100 | CTnI           | Similar postoperative cTnI peak levels in both groups                  | [115]     |
| CABG          | Sevoflurane during surgery and postoperatively, not during CPB | Propofol | Remifentanil | 73 | CTnI           | Similar postoperative cTnI peak levels in both groups                  | [116]     |
| OPCAB         | Sevoflurane 1–2% or desflurane 4–6% during surgery | Propofol | Fentanyl | 139 | CTnT           | Similar postoperative cTnT levels in all three groups up to 96 h after surgery | [117]     |

CABG, coronary artery bypass graft surgery; MAC, minimal alveolar concentration; CPB, cardiopulmonary bypass; CTnI, cardiac troponin I; MIDCAB, minimally invasive direct coronary artery bypass surgery; CTnT, cardiac troponin T; LAD, left anterior descending artery; OPCAB, off-pump coronary artery bypass graft surgery; AUC, area under the curve; MVR, mitral valve replacement; CAD, coronary artery disease; CC, aortic cross-clamp.
during CABG without CPB, by analysing lipid peroxidation and nitrosative stress biomarkers from the coronary sinus. These remained constant in the sevoflurane group, but were significantly increased in the control group receiving propofol, suggesting that oxidative stress is reduced with sevoflurane [114]. Suryaprapaksh et al. studied 139 patients undergoing CABG without CPB, randomly allocated to anaesthesia using sevoflurane, desflurane or propofol [117]. Postoperative troponin levels were similar in all study groups, possibly owing to insufficient statistical power [117].

It is hard to draw firm conclusions from these results, with some studies showing beneficial effects of volatile anaesthetics, others demonstrating beneficial effects of propofol, and one recent study showing that a combination of volatile anaesthetics plus propofol provides optimal myocardial protection. Similarly, different administration patterns of volatile anaesthetics during surgery, and only before CPB, have been shown to be beneficial. This variability may be a result of different anaesthetic and surgical techniques, operations, patient co-morbidities and peri-operative drug administration. Another issue to consider is that troponin release after cardiac surgery does not always indicate irreversible myocardial damage, as has been demonstrated recently by Pegg and colleagues, using delayed enhancement cardio-MRI after CABG surgery [90]. The release pattern of troponin from myocardial tissues occurs in two phases: an initial troponin peak between 1 h and 6 h postoperatively, with non-necrotic/reversible myocardial injury and troponin release from the cytoplasmic compartment, due to CPB; and a delayed and sustained secondary release pattern with a peak after 24 h, caused by degradation of the contractile myofibril apparatus, inducing necrosis. Pegg et al. concluded that either several postoperative troponin measurements resulting in a washout curve (area under the curve), or equally a 24-h post-surgery single measurement of troponin I, correlate best with new postoperative myocyte necrosis. This differential picture of troponin release may further explain contradictory results in the assessment of preconditioning using volatile anaesthetics, with troponin levels as the primary outcome measure.

Apart from ischaemic markers, inflammatory markers may be reduced in patients receiving volatile anaesthetic agents, which may have a beneficial effect on postoperative morbidity and mortality. For example, sevoflurane reduced interleukin (IL)-6 and IL-8 concentrations in patients undergoing CABG surgery compared with propofol [95]. In another clinical trial, sevoflurane 2% was added to the cardioplegia, which resulted in a reduced postoperative inflammatory response, indicated by lower IL-6, CD11b/CD18, and TNF-alpha serum levels postoperatively, compared with a control group receiving only propofol [120].

In summary, it is evident from the above clinical proof-of-concept trials that all three volatile anaesthetics (isoflurane, desflurane and sevoflurane) have the potential to provide myocardial protection, and also that some patterns of administration, e.g. during the whole surgical procedure and intermittently before CPB, may increase the potential protection from volatile anaesthetics. In addition, recent data have suggested that a combination of volatile anaesthetics and a high dose of propofol during bypass and reperfusion might increase myocardial protection [102].

So far, clinical trials have been too small to investigate the effects of volatile anaesthetics on clinical outcomes such as postoperative myocardial infarction and mortality. Nevertheless, clinical outcome has been addressed by two retrospective longitudinal studies and by recent meta-analyses. In the longitudinal studies, a total of 34 310 patients undergoing CABG in 64 Italian cardiac surgery centres, and 10 535 consecutive patients undergoing cardiac surgery in three Danish centres, were studied; both suggested that the use of volatile anaesthetic agents is associated with a decline in 30-day mortality [121, 122]. One meta-analysis of 2979 patients in 27 trials showed that the protective intracellular effects of volatile anaesthetic agents on the myocardium in patients undergoing CABG surgery resulted in reduced postoperative troponin I levels, higher cardiac indices and a lower requirement for inotropic support [123]. However, the authors were unable to demonstrate a significant clinical benefit from volatile anaesthetics on other outcome variables such as myocardial infarction or mortality, predominantly because the studies were small, with low statistical power for clinical endpoints. In another meta-analysis, including 2841 patients from 32 clinical trials, Yu and Beattie found no difference in
postoperative myocardial infarction or in-hospital mortality [124]. Similarly, Yao and Li, who assessed the potential beneficial effects of sevoflurane on clinical outcome in 696 patients, did not find any differences in postoperative myocardial infarction or mortality [125].

In contrast, another meta-analysis of 1922 patients from 22 clinical trials showed a reduction in postoperative myocardial infarction and mortality with the use of volatile anaesthetics [126]. Only proof-of-concept studies investigating sevoflurane or desflurane were included, and the volatile anaesthetics were mainly administered throughout the cardiac surgery, or before CPB. Recently, Landoni et al. published another meta-analysis with the largest number of patients so far, assessing clinical outcomes and anaesthetic preconditioning [127]. A total of 3642 patients from 38 trials were included. Postoperative mortality was doubled in patients receiving total intravenous anaesthesia, compared with those receiving volatile anaesthetics in cardiac surgery, from 25/1994 (1.3%) in the volatile anaesthetic group to 43/1648 (2.6%) in the group of patients receiving intravenous anaesthesia. Despite the relatively large number of patients, the authors commented that the number of patients enrolled in clinical trials investigating the potential benefits of volatile anaesthetics in cardiac surgery is still low, and that there is a need for large randomised trials. Limitations of the above meta-analyses include the potentially suboptimal quality and heterogeneity of the proof-of-concept trials that were included, as well as the different secondary endpoints.

Conclusions

There is evidence from experimental in-vitro and in-vivo trials that volatile anaesthetics have a beneficial effect, by inducing myocardial protection. This body of evidence includes not only animal studies, but also in-vitro analysis of human myocardial muscle tissue or cells. The translation of the experimental evidence into clinical practice has, to date, resulted in many small- to medium-sized proof-of-concept trials, with only surrogate myocardial ischaemic markers as the primary outcome measure. The results of these trials are promising, with many studies indicating a beneficial effect of volatile anaesthetics in patients undergoing cardiac surgery. However, they remain inconclusive. The evidence has not been convincingly translated from experimental studies into the clinical setting, and there is still a high degree of variability in anaesthetic techniques, with different administration patterns, including volatile anaesthetics and/or propofol [128, 129]. Larger pragmatic, multicentre trials are therefore required to investigate whether volatile anaesthetic agents in cardiac surgery have the potential to reduce the incidence and severity of major adverse clinical endpoints, such as peri-operative cardiac events, or postoperative mortality [130]. The results of these multicentre clinical outcome trials will be necessary to inform the evidence base, and change our clinical practice.

Competing interests

AAK is an Editor of Anaesthesia and this paper has undergone an additional external review as a result. No external funding declared.

References

1. Biancari F, Kangasniemi OP, Aliasim Mahar M, et al. Changing risk of patients undergoing coronary artery bypass surgery. Interactive Cardiovascular and Thoracic Surgery 2009; 8: 40–4.
2. Hedberg M, Engstrom KG. Stroke after cardiac surgery – hemispheric distribution and survival. Scandinavian Cardiovascular Journal 2013; 47: 136–44.
3. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. New England Journal of Medicine 2012; 367: 30–9.
4. Suleiman MS, Hancock M, Shukla R, Rajakaruna C, Angelini GD. Cardioplegic strategies to protect the hypertrophic heart during cardiac surgery. Perfusion 2011; 26(Suppl 1): 48–56.
5. Murty CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–36.
6. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. New England Journal of Medicine 2007; 357: 1121–35.
7. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circulation Research 1993; 72: 1293–9.
8. Pagel PS. Postconditioning by volatile anaesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. Journal of Cardiothoracic and Vascular Anesthesia 2008; 22: 753–65.
9. Jivraj N, Liew F, Marber M. Ischaemic postconditioning: cardiac protection after the event. Anaesthesia 2015; 70: doi: 10.1111/anae.12974.
10. Sivaraman V, Pickard MJ, Hausenloy DJ. Remote ischaemic conditioning: cardiac protection from afar. Anaesthesia 2015; 70: doi: 10.1111/anae.12973.
11. Bland JH, Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology 1976; 45: 287–93.
12. Davis RF, DeBoer LW, Rude RE, Lowenstein E, Maroko PR. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion. *Anesthesiology* 1983; 59: 402–11.

13. van Ackern K, Vetter HO, Bruckner UB, Madler C, Mittman U, Peter K. Effects of enflurane on myocardial ischaemia in the dog. *British Journal of Anaesthesia* 1985; 57: 497–504.

14. Davis RF, Sidi A. Effect of isoflurane on the extent of myocardial necrosis and on systemic hemodynamics, regional myocardial blood flow, and regional myocardial metabolism in dogs after coronary artery occlusion. *Anesthesia and Analgesia* 1989; 69: 575–86.

15. Buffington CW, Romson JL, Levine A, Duttlinger NC, Huang AH. Isoflurane induces coronary steal in a canine model of chronic coronary occlusion. *Anesthesiology* 1987; 66: 280–92.

16. Moore PG, Kien ND, Reitan JA, White DA, Safwat AM. No evidence for blood flow redistribution with isoflurane or halothane during acute coronary artery occlusion in fentanyl-anesthetized dogs. *Anesthesiology* 1991; 75: 854–65.

17. Cason BA, Gamperl AK, Slocum RE, Hickey RF. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. *Anesthesiology* 1997; 87: 1182–90.

18. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. *Anesthesiology* 1997; 86: 699–709.

19. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Waeltier DC. Isoflurane mimics ischemic preconditioning via activation of KATP channels: reduction of myocardial infarct size with an acute memory phase. *Anesthesiology* 1997; 87: 361–70.

20. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. *Cardiovascular Research* 2004; 61: 448–60.

21. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? *Journal of Molecular and Cellular Cardiology* 2009; 47: 32–40.

22. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. *Basic Research in Cardiology* 2009; 104: 189–202.

23. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. *American Journal of Physiology* 2003; 285: H921–30.

24. Kubi DA, Gustafsson AB. Mitochondria and mitophagy: the Yin and yang of cell death control. *Circulation Research* 2012; 111: 1208–21.

25. Xie M, Kong Y, Tan W, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. *Circulation* 2014; 129: 1139–51.

26. Bouwman RA, Musters Rj, van Beek-Harmsen Bg, de Lange Jj, Boer C. Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphatase-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. *Anesthesiology* 2004; 100: 506–14.

27. Ludwig LM, Weihrach D, Kersten JR, Pagel PS, Waeltier DC. Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. *Anesthesiology* 2004; 100: 532–9.

28. Toma O, Weber NC, Wolter JJ, Obal D, Preckel B, Schlack W. Desflurane preconditioning induces time-dependent activation of protein kinase C epsilon and extracellular signal-regulated kinase 1 and 2 in the rat heart in vivo. *Anesthesiology* 2004; 101: 1372–80.

29. Bouwman RA, Salic K, Pading FG, et al. Cardioprotection via activation of protein kinase C-delta depends on modulation of the reverse mode of the Na+/Ca2+ exchanger. *Circulation* 2006; 114: 1226–32.

30. Pravdic D, Sedlic F, Mio Y, Vladic N, Bienengraeber M, Bosnjak ZJ. Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein kinase C-epsilon-mediated pathway. *Anesthesiology* 2009; 111: 267–74.

31. Okusa C, Miyamae M, Sugioka S, et al. Acute memory phase of sevoflurane preconditioning is associated with sustained translocation of protein kinase C-alpha and epsilon, but not delta, in isolated guinea pig hearts. *European Journal of Anaesthesiology* 2009; 26: 582–8.

32. Mellidis K, Ordovi V, Galatou E, et al. Activation of prosurvival signaling pathways during the memory phase of volatile anesthetic preconditioning in human myocardium: a pilot study. *Molecular Cellular Biochemistry* 2014; 388: 195–201.

33. Wang C, Weihrach D, Schwabe DA, et al. Extracellular signal-regulated kinases trigger isoflurane preconditioning concomitant with upregulation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in rats. *Anesthesia and Analgesia* 2006; 103: 281–8.

34. Raphael J, Abedat S, Rivo J, et al. Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins. *Journal of Pharmacology and Experimental Therapeutics* 2006; 318: 186–94.

35. Lambers RR, Onderwater G, Hamdani N, et al. Reactive oxygen species-induced stimulation of SAMP-activated protein kinase mediates sevoflurane-induced cardioprotection. *Circulation* 2009; 120: S10–5.

36. Alcinod D, Krolkowski JG, Pagel PS, Waeltier DC, Kersten JR. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. *Anesthesiology* 2004; 100: 547–54.

37. Horikawa YT, Patel HH, Tsutsumi YM, et al. Caveolin-3 expression and caveolae are required for isoflurane-induced cardiac protection from hypoxia and ischemia/reperfusion injury. *Journal of Molecular and Cellular Cardiology* 2008; 44: 123–30.

38. Zhao J, Wang F, Zhang Y, et al. Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition. *Circulation* 2013; 128: S121–9.

39. Tsai SK, Lin SM, Huang CH, Hung WC, Chih CL, Huang SS. Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits. *Life Sciences* 2004; 76: 651–60.

40. Smul IM, Lange M, Redel A, Burkhard N, Roewer N, Kehl F. Desflurane-induced preconditioning against myocardial infarction is mediated by nitric oxide. *Anesthesiology* 2006; 105: 719–25.

41. Ludwig LM, Tanaka K, Eells JT, et al. Preconditioning by isoflurane is mediated by reactive oxygen species generated...
from mitochondrial electron transport chain complex III. 

Anesthesia and Analgesia 2004; 99: 1308–15.

42. Riess ML, Eells JT, Kevin LG, Camara AK, Henry MM, Stowe DF. Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology 2004; 100: 498–505.

43. Bouwman RA, Musters RJ, van Beek-Harmsen BJ, et al. Sevoflurane-induced cardioprotection depends on PKC-alpha activation via production of reactive oxygen species. British Journal of Anaesthesia 2007; 99: 639–45.

44. Hanouz JJ, Zhu L, Lemoine S, et al. Reactive oxygen species mediate sevoflurane- and desflurane-induced preconditioning in isolated human right atria in vitro. Anesthesia and Analgesia 2007; 105: 1534–9.

45. Sedlíc F, Pravdic D, Ljubkovic M, Marinovic J, Stadnicky A, Bosnjak ZJ. Differences in production of reactive oxygen species and mitochondrial uncoupling as events in the preconditioning signaling cascade between desflurane and sevoflurane. Anesthesia and Analgesia 2009; 109: 405–11.

46. Sepac A, Sedlíc F, Si-Tayeb K, et al. Isoflurane preconditioning elicits competent endogenous mechanisms of protection from oxidative stress in cardiomyocytes derived from human embryonic stem cells. Anesthesiology 2010; 113: 906–16.

47. Hirata N, Shim YH, Pravdic D, et al. Isoflurane differentially modulates mitochondrial reactive oxygen species production via forward versus reverse electron transport flow: implications for preconditioning. Anesthesiology 2011; 115: 531–40.

48. Piriou V, Chiari P, Gateau-Roesch Q, et al. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 2004; 100: 581–8.

49. Krollkowski JG, Bienengraeber M, Weihrauch D, Wartier DC, Kersten JR, Pagel PS. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesthesia and Analgesia 2005; 101: 1590–6.

50. Hirose K, Tsutsumi YM, Tsutsumi R, et al. Role of the O-linked beta-N-acetylglucosamine in the cardioprotection induced by isoflurane. Anesthesiology 2011; 115: 955–62.

51. Jiang MT, Nakae Y, Ljubkovic M, Kwok WM, Stowe DF, Bosnjak ZJ. Isoflurane activates human cardiac mitochondrial adenosine triphosphate-sensitive K+ channels reconstituted in lipid bilayers. Anesthesia and Analgesia 2007; 105: 926–32, table of contents.

52. Redel A, Lange M, Jažbutyte V, et al. Activation of mitochondrial high-conductance calcium-activated K+ channels via protein kinase A mediates desflurane-induced preconditioning. Anesthesia and Analgesia 2008; 106: 384–91.

53. Zhong C, Zhou Y, Liu H. Nuclear factor kappaB and anesthetic preconditioning during myocardial ischemia-reperfusion. Anesthesiology 2004; 100: 540–6.

54. Lu X, Liu H, Wang L, Schaefer S. Activation of NF-kappaB is a critical element in the antiapoptotic effect of anesthetic preconditioning. American Journal of Physiology 2009; 296: H1296–304.

55. Konia MR, Schaefer S, Liu H. Nuclear factor-[kappa]B inhibition provides additional protection against ischaemia/reperfusion injury in delayed sevoflurane preconditioning. European Journal of Anaesthesiology 2009; 26: 496–503.

56. Wang C, Xie H, Liu X, et al. Role of nuclear factor-kappaB in volatile anesthetic preconditioning with sevoflurane during myocardial ischaemia/reperfusion. European Journal of Anaesthesiology 2010; 27: 747–56.

57. Raphael J, Zuo Z, Abedat S, Beeri R, Gozal Y. Isoflurane preconditioning decreases myocardial infarction in rabbits via up-regulation of hypoxia inducible factor 1 that is mediated by mammalian target of rapamycin. Anesthesiology 2008; 108: 415–25.

58. Li Y, Zhang X, Zhu B, Xue Z. Desflurane preconditioning inhibits endothelial nuclear factor-kappaB activation by targeting the proximal end of tumor necrosis factor-alpha signaling. Anesthesia and Analgesia 2008; 106: 1473–9.

59. Blao J, Zhanggang X, Hao J, Changhong M, Jing C. The in vitro effect of desflurane preconditioning on endothelial adhesion molecules and mRNA expression. Anesthesia and Analgesia 2005; 100: 1007–13.

60. Weber NC, Kandler J, Schlack W, Grueber Y, Frassdorf J, Preckel B. Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alpha-induced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology 2008; 108: 199–207.

61. Lucchini E, Ambrosio S, Aguirre J, et al. Sevoflurane inhalation at sedative concentrations provides endothelial protection against ischemia-reperfusion injury in humans. Anesthesiology 2007; 106: 262–8.

62. Annecke T, Chappell D, Chen C, et al. Sevoflurane preserves the endothelial glycocalyx against ischaemia-reperfusion injury. British Journal of Anaesthesia 2010; 104: 214–22.

63. Fung J, Zuo Z. Isoflurane preconditioning increases endothelial cell tolerance to in-vitro simulated ischaemia. Journal of Pharmacokinetics and Pharmacology 2011; 63: 106–10.

64. Redel A, Stumpner J, Smul TM, et al. Endothelial nitric oxide synthase mediates the first and inducible nitric oxide synthase mediates the second window of desflurane-induced preconditioning. Journal of Cardiothoracic and Vascular Anaesthesia 2013; 27: 494–501.

65. Frassdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. British Journal of Anaesthesia 2009; 103: 89–98.

66. Pagel PS, Hudetz JA. Delayed cardioprotection by inhaled anesthetics. Journal of Cardiothoracic and Vascular Anesthesia 2011; 25: 1125–40.

67. Van Allen NR, Krafft PR, Leitzke AS, Applegate RL 2nd, Tang Y, Zhang JH. The role of volatile anesthetics in cardioprotection: a systematic review. Medical Gas Research 2012; 2: 8.

68. Pagel PS. Myocardial protection by volatile anesthetics in patients undergoing cardiac surgery: a critical review of the laboratory and clinical evidence. Journal of Cardiothoracic and Vascular Anaesthesia 2013; 27: 972–82.

69. Lang XE, Wang X, Jin JH. Mechanisms of cardioprotection by isoflurane against I/R injury. Frontiers in Biosciences 2013; 18: 387–93.

70. Swyers T, Redford D, Larson DF. Volatile anesthetic-induced preconditioning. Perfusion 2014; 29: 10–5.

71. Redel A, Stumpner J, Tischkowitz T, et al. Comparison of isoflurane-, sevoflurane-, and desflurane-induced pre- and postconditioning against myocardial infarction in mice in vivo. Experimental Biology and Medicine 2009; 234: 1186–91.

72. Riess ML, Kevin LG, Camara AK, Heisner JS, Stowe DF. Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts. Anesthesiology 2004; 100: 569–74.

73. Smul TM, Stumpner J, Blomhøj C, et al. Propofol inhibits desflurane-induced preconditioning in rabbits. Journal of Cardiothoracic and Vascular Anaesthesia 2011; 25: 276–81.
74. Sun HY, Xue FS, Xu YC, et al. Propofol improves cardiac functional recovery after ischemia-reperfusion by upregulating nitric oxide synthase activity in the isolated rat hearts. Chinese Medical Journal 2009; 122: 3048–54.

75. Li T, Wu W, You Z, et al. Alternative use of isoflurane and propofol confers superior cardioprotection than using one of them alone in a dog model of cardiopulmonary bypass. European Journal of Pharmacology 2012; 677: 138–46.

76. Weinrauch D, Krolkowski JG, Bienengraeber M, Kersten JR, Wartliy DC, Pagel PS. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesthesia and Analgesia 2005; 101: 942–9.

77. Lemoine S, Zhu L, Massetti M, Gerard JL, Hanouz JL. Continuous administration of remifentanil and sufentanil induces cardioprotection in human myocardium, in vitro. Acta Anesthesiologica Scandinavica 2011; 55: 758–64.

78. Masui K, Kashimoto S, Furuya A, Oguchi T. Isoflurane and sevoflurane during reperfusion prevent recovery from ischaemia in mitochondrial KATP channel blocker pretreated hearts. European Journal of Anaesthesiology 2006; 23: 123–9.

79. Lange M, Smul TM, Redel A, et al. Differential role of calcium/calmodulin-dependent protein kinase II in desflurane-induced preconditioning and cardioprotection by metoprolol: metoprolol blocks desflurane-induced preconditioning. Anesthesiology 2008; 109: 72–80.

80. Canfield SG, Sepac A, Sedic F, Muravyeva MY, Bai X, Bosnjak ZJ. Marked hyperglycemia attenuates anesthetic preconditioning in human-induced pluripotent stem cell-derived cardiomyocytes. Anesthesiology 2012; 117: 735–44.

81. Song T, Lv LY, Xu J, et al. Diet-induced obesity suppresses sevoflurane preconditioning against myocardial ischemia-reperfusion injury: role of AMP-activated protein kinase pathway. Experimental Biological Medicine 2011; 236: 1427–36.

82. Ma LL, Zhang FJ, Qian LB, et al. Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of the M653/RISK/GSK3beta signaling. International Journal of Cardiology 2013; 168: 3671–8.

83. Ma LL, Zhang FJ, Kong FJ, et al. Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3beta signals. Shock 2013; 40: 217–21.

84. Riess ML, Camara AK, Rhodes SS, McCormick J, Jiang MT, Stowe DF. Increasing heart size and age attenuate anesthetic preconditioning in guinea pig isolated hearts. Anesthesia and Analgesia 2005; 101: 1572–6.

85. Mio Y, Bienengraeber MW, Marinovic J, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcosomal adenine triphosphate-sensitive potassium channel activity. Anesthesiology 2008; 108: 612–20.

86. Diaz RJ, Wilson GJ. Studying ischemic preconditioning in isolated cardiomyocyte models. Cardiovascular Research 2006; 70: 286–96.

87. Taege M, Moyer H, Sen S, Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Annals of the New York Academy of Sciences 2010; 1188: 191–8.

88. Peters J. Remote ischemic preconditioning of the heart: remote questions, remote importance, or remote preconditioning? Basic Research in Cardiology 2011; 106: 507–9.

89. Croal BL, Hills GS, Gibson PH, et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006; 114: 1468–75.

90. Pegg Tj, Maunsell Z, Karamitros TD, et al. Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction after coronary artery bypass grafting: insights from serial cardiac MRI. Heart 2011; 97: 810–6.

91. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalties of its administration. Anesthesiology 2004; 101: 299–310.

92. Lee MC, Chen CH, Kuo MC, Kang PL, Lo A, Liu K. Isoflurane preconditioning-induced cardiac protection in patients undergoing coronary artery bypass grafting. European Journal of Anaesthesiology 2006; 23: 841–7.

93. Cromheecke S, Pepermans V, Hendrickx E, et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesthesia and Analgesia 2006; 103: 289–96, table of contents.

94. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. Journal of Cardiothoracic and Vascular Anesthesia 2006; 20: 477–83.

95. Kawamura T, Kadosaki M, Nara N, et al. Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. Journal of Cardiothoracic and Vascular Anesthesia 2006; 20: 503–8.

96. Meco M, Cirri S, Gallazzi C, Magnani G, Cossetta D. Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo-controlled study. European Journal of Cardiothoracic Surgery 2007; 32: 319–25.

97. Tritapepe L, Landoni G, Guarracino F, et al. Cardiac protection by volatile anaesthetics: a multicentre randomised controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. European Journal of Anaesthesiology 2007; 24: 323–31.

98. Bein B, Renner J, Caliebe D, et al. The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardio-pulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anesthesiology 2008; 109: 1046–55.

99. Frassdorf J, Borowski A, Ebel D, et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery 2009; 137: 1436–42, e1–2.

100. Amr YM, Yassin IM. Cardiac protection during on-pump coronary artery bypass grafting: ischemic versus isoflurane preconditioning. Seminars in Cardiothoracic and Vascular Anesthesia 2010; 14: 205–11.

101. Tempe DK, Dutta D, Garg M, Minhas H, Tomar A, Virmani S. Myocardial protection with isoflurane during off-pump coronary artery bypass grafting: a randomized trial. Journal of Thoracic and Cardiovascular Anesthesia 2011; 25: 59–65.

102. Huang Z, Zhong X, Irwin MG, et al. Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients. Clinical Science 2011; 121: 57–69.

103. Wang J, Zheng H, Chen CL, Lu W, Zhang YQ. Sevoflurane at 1 MAC provides optimal myocardial protection during off-
pump CABG. *Scandinavian Cardiovascular Journal* 2013; **47**: 175–84.

104. Wang X, Jarvinen O, Kuukasjarvi P, et al. Isoflurane produces only minor preconditioning in coronary artery bypass grafting. *Scandinavian Cardiovascular Journal* 2004; **38**: 287–92.

105. Bein B, Renner J, Calieber D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. *Anaesthesia and Analgesia* 2005; **100**: 610–6.

106. Xia Z, Huang Z, Ansley DM. Large-dose propofol during cardiopulmonary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: a comparison with isoflurane. *Anaesthesia and Analgesia* 2006; **103**: 527–32.

107. Law-Koune JD, Raynaud C, Liu N, Dubois C, Romano M, Fischer M. Sevoflurane-remifentanil versus propofol-remifentanil anaesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. *Journal of Cardiothoracic and Vascular Anaesthesia* 2006; **20**: 484–92.

108. Lucchinetti E, Hofer C, Bestmann L, et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. *Anesthesiology* 2007; **106**: 444–57.

109. Piriou V, Mantz J, Goldfarb G, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. *British Journal of Anaesthesia* 2007; **99**: 624–31.

110. Landoni G, Calabro MG, Marchetti C, et al. Desflurane versus propofol in patients undergoing mitral valve surgery. *Journal of Cardiothoracic and Vascular Anaesthesia* 2007; **21**: 672–7.

111. De Hert S, Vlasselaers D, Barbe R, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. *Anaesthesia* 2009; **64**: 953–60.

112. Flier S, Post J, Concepcion AN, Kappen TH, Kalkman CJ, Buhr WF. Influence of propofol-opioid vs isoflurane-opioid anaesthesia on postoperative troponin release in patients undergoing coronary artery bypass grafting. *British Journal of Anaesthesia* 2010; **105**: 122–30.

113. Kim TY, Kim DK, Yoon TG, et al. Myocardial injury in remifentanil-based anaesthesia for off-pump coronary artery bypass surgery: an equipotent dose of sevoflurane versus propofol. *Anaesthesia and Intensive Care* 2011; **39**: 418–25.

114. Ballester M, Llorens J, García-de-la-Asunció J, et al. Myocardial oxidative stress protection by sevoflurane vs propofol: a randomised controlled study in patients undergoing off-pump coronary artery bypass graft surgery. *European Journal of Anaesthesiology* 2011; **28**: 874–81.

115. Biglami E, Landoni G, Gerli C, et al. Sevoflurane vs propofol in patients with coronary disease undergoing mitral surgery: a randomised study. *Acta Anaesthesiologica Scandinavica* 2012; **56**: 482–90.

116. Soro M, Gallego I, Silva V, et al. Cardioprotective effect of sevoflurane and propofol during anaesthesia and the post-operative period in coronary bypass graft surgery: a double-blind randomised study. *European Journal of Anaesthesiology* 2012; **29**: 561–9.

117. Suryaprakash S, Chakravarthy M, Muniraju G, et al. Myocardial protection during off pump coronary artery bypass surgery: a comparison of inhalational anaesthesia with sevoflurane or desflurane and total intravenous anesthesia. *Annals of Cardiac Anaesthesia* 2013; **16**: 4–8.

118. Kahraman S, Demiryurek A. Propofol is a peroxynitrite scavenger. *Anaesthesia and Analgesia* 1997; **84**: 1127–9.

119. Kevin LG, Katz P, Camara AK, Novotila E, Riess ML, Stowe DF. Anesthetic preconditioning: effects on latency to ischemic injury in isolated hearts. *Anaesthesiology* 2003; **99**: 385–91.

120. Nader ND, Li CM, Khadra WZ, Reedy R, Panos AL. Anesthetic myocardial protection with sevoflurane. *Journal of Cardiothoracic and Vascular Anaesthesia* 2004; **18**: 269–74.

121. Bignami E, Biondi-Zoccai G, Landoni G, et al. Volatile anesthetics reduce mortality in cardiac surgery. *Journal of Cardiothoracic and Vascular Anaesthesia* 2009; **23**: 594–9.

122. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anaesthesia on outcome in 10,535 cardiac surgical procedures. *Journal of Cardiothoracic and Vascular Anaesthesia* 2007; **21**: 664–71.

123. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. *British Journal of Anaesthesia* 2006; **97**: 127–36.

124. Yu CH, Beattie WS. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. *Canadian Journal of Anaesthesia* 2006; **53**: 906–18.

125. Yao YT, Li LH. Sevoflurane versus propofol for myocardial protection in patients undergoing coronary artery bypass grafting surgery: a meta-analysis of randomized controlled trials. *Chinese Medical Sciences Journal* 2009; **24**: 133–41.

126. Landoni G, Biondi-Zoccai GG, Zangrillo A, et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. *Journal of Cardiothoracic and Vascular Anaesthesia* 2007; **21**: 502–11.

127. Landoni G, Greco T, Biondi-Zoccai G, et al. Anaesthetic drugs and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery. *British Journal of Anaesthesia* 2013; **111**: 886–96.

128. Bein B. Clinical application of the cardioprotective effects of volatile anaesthetics: PRO – get an extra benefit from a proven anaesthetic free of charge. *European Journal of Anaesthesiology* 2011; **28**: 620–2.

129. Van Rompaey N, Barvais L. Clinical application of the cardioprotective effects of volatile anaesthetics: CON – total intravenous anaesthesia or not total intravenous anaesthesia to anaesthetise a cardiac patient? *European Journal of Anaesthesiology* 2011; **28**: 623–7.

130. Kunst G. From coronary steal to myocardial, renal, and cerebral protection: more questions than answers in anaesthetic preconditioning? *British Journal of Anaesthesia* 2014; **112**: 958–60.